Announcement of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. on using idle raised funds for cash management and redemption at maturity and continuing cash management
Securities code: 603456 Securities abbreviation: Jiuzhou Pharmaceutical Announcement number: 2025-062 Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Announcement on using idle raised funds for cash management maturity redemption and continuing cash management
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Cash management trustee: Agricultural Bank of China Co., Ltd. Changshu Economic Development Zone Branch (hereinafter referred to as "Agricultural Bank of China Changshu Economic Development Zone Branch");
The amount of cash management this time: 40 million yuan;
Cash management products: bank deposit certificates;
Cash management period: 6 months;
Review procedures for implementation: Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company", "Jiuzhou Pharmaceutical") held the 11th meeting of the 8th board of directors and the 7th meeting of the 8th board of supervisors on December 13, 2024, and reviewed and approved the "Proposal on the use of idle raised funds for cash management", agreeing that the company and its subsidiaries will use no more than RMB 12 on the premise of ensuring the safety of funds and ensuring that the construction and use plans of investment projects with raised funds will not be affected. The idle raised funds of RMB 100 million can be used to purchase investment products with high security and good liquidity (including but not limited to structured deposits, time deposits, certificates of deposit, notice deposits, income certificates and financial products of banks or securities companies, etc.) in a timely manner, and such investment products shall not be used for pledge, and shall not be used for investment activities for the purpose of securities investment. The term shall not exceed 12 months from the date of approval by the board of directors, and the term of a single investment product shall not exceed 12 months. This matter does not need to be submitted to the shareholders' meeting for consideration. For details, please refer to the relevant announcements disclosed by the company on the Shanghai Stock Exchange website (www.sse.com) and the Shanghai Securities News on December 14, 2024;
Special risk warning: Although the cash management product purchased this time has high safety and good liquidity, the financial market is greatly affected by macroeconomic, fiscal and monetary policies, and it cannot be ruled out that this investment may be affected by market fluctuations.
1. The use of temporarily idle raised funds to purchase cash management products due to redemption status
On July 28, 2025, subsidiaries Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. and Ruibo (Suzhou) Pharmaceutical Co., Ltd. respectively used temporarily idle raised funds to purchase cash management products. For details, please refer to the "Zhejiang Jiuzhou Pharmaceutical Co., Ltd.'s Progress Announcement on Opening a Special Settlement Account for Cash Management Products of Raised Funds and Using Idle Raised Funds for Cash Management" disclosed by the company on July 30, 2025 (Announcement Number: 2025-044). As of the date of this announcement, the company has redeemed some of its expired products. The specific redemption details are as follows:
Product Amount Actual annualization Actual income Purchaser Trustee Value date Maturity date
Type (10,000 yuan) Yield (10,000 yuan) Jiuzhou Pharmaceutical Industrial and Commercial Bank of China
Large amount
(Taizhou) Yes, Taizhou Jiaojiang 5,000 2025/7/28 2025/10/28 0.90% 11.25
certificate of deposit
Co., Ltd. Branch
Large amount
Ruibo (Suzhou) Agricultural Bank of China 2,000 2025/7/28 2025/10/28 0.90% 4.50
certificate of deposit
Pharmaceutical Co., Ltd. Mature Economic Development
Large amount
Division District Branch 4,000 2025/7/28 2025/10/28 0.90% 9.00 Certificate of Deposit
2. Overview of this cash management
(1) Cash management purpose
On the premise of ensuring the construction and use of investment projects with funds raised by the company and its subsidiaries, we can better utilize capital efficiency, improve the efficiency of the company's use of funds, maintain and increase the value of the company's cash assets, and protect the interests of the company and shareholders.
(2) Cash management amount
40 million yuan.
(3) Source of funds
As approved by the China Securities Regulatory Commission's "Reply on Approving the Non-public Issuance of Stocks by Zhejiang Jiuzhou Pharmaceutical Co., Ltd." (CSRC License [2021] No. 97), the company non-publicly issued 26,171,159 RMB ordinary shares (A shares) at an issue price of 38.21 yuan/share, and the total raised funds were RMB 999,999,985.39 yuan, after deducting various issuance expenses in RMB 9,380,611.68 yuan (excluding tax), and the actual net amount of funds raised was RMB 990,619,373.71. The receipt of the above-mentioned raised funds has been verified by Tianjian Accounting Firm (Special General Partnership), and Tianjian Yan (2021) No. 36 "Capital Verification Report" was issued on January 29, 2021 for verification, and the raised funds were stored in a special account. As of December 31, 2024, the company's investment projects with funds raised from non-public offerings in 2020 are as follows:
Planned use of raised funds Cumulative investment amount Serial number can be used when reaching predetermined date Project name
(10,000 yuan) (10,000 yuan) Researched by Status Time Ruibo (Suzhou) Pharmaceutical Co., Ltd.
1 28,000.00 22,959.30 Center project to be launched in December 2025
Research by Jiuzhou Pharmaceutical (Hangzhou) Co., Ltd.
2 13,700.00 8,851.63 Center project to be launched in December 2024
Acquired 100% equity of Zhongshan Pharmaceutical Factory
3 And increase capital to implement CDMO preparation reform and expansion 18,500.00 14,431.21 Project to be built in June 2026
Zhejiang Siwei Pharmaceutical Technology Co., Ltd.
4 11,800.00 11,827.37 Ten billion tablet preparation project in December 2022 (Phase I)
5 Supplementary working capital 27,061.94 [Note 1] 27,094.97 -Total 99,061.94 85,164.48 -Note 1: Due to deduction of issuance expenses.
(4) Basic information on cash management products
whether whether it is
Is it consistent with the existence of
Security in disguise
Estimated annual change in product name, product category, product period, investment income, income
Trustee name, high return, fundraising type, limit type, close
Rate (%) Liquidity link
Good sex, purpose sex
Transactions of need
Seek for
Agricultural Bank of China often maintains capital
Large deposit Ordinary large 4,000
Mature economic development 6 months fixed 1.10% No Yes No Single deposit unit 10,000 yuan
District branch income
This time, 40 million yuan of idle raised funds were used for cash management, which met the requirements of high security and good liquidity. There was no disguised change in the use of raised funds, and it did not affect the normal progress of the raised investment projects. This cash management was within the limit authorized by the board of directors and did not exceed the authorized use period. The company and its subsidiaries have no related relationship with the contracted bank for the above cash management, and the above cash management does not constitute a related transaction.
(5) Cash management income distribution
The proceeds obtained by the company and its subsidiaries from using idle raised funds for cash management belong to the company and its subsidiaries. After the cash management expires, they will be returned to the special account for raised funds in a timely manner, and the raised funds will be managed and used in strict accordance with the requirements of the China Securities Regulatory Commission and the Shanghai Stock Exchange on regulatory measures for raised funds.
3. Review procedure
The company held the 11th meeting of the 8th board of directors and the 7th meeting of the 8th board of supervisors on December 13, 2024, and reviewed and approved the "Proposal on the Use of Idle Raised Funds for Cash Management", agreeing that the company and its subsidiaries will use no more than RMB 12 The idle raised funds of RMB 100 million can be used to purchase investment products with high security and good liquidity (including but not limited to structured deposits, time deposits, certificates of deposit, notice deposits, income certificates and financial products of banks or securities companies, etc.) in a timely manner, and such investment products shall not be used for pledge, and shall not be used for investment activities for the purpose of securities investment. The term shall not exceed 12 months from the date of approval by the board of directors, and the term of a single investment product shall not exceed 12 months. The company's board of directors authorizes the management to exercise the investment decision-making power and sign relevant documents within the above-mentioned use period, fund amount, and product scope, and the finance department is responsible for the specific implementation. Within the above-mentioned period and quota range, funds can be used on a rolling basis. The company's sponsor has issued a concurring opinion.
4. Investment risk analysis and risk control measures
(1) Investment risks
Although the cash management products purchased by the company and its subsidiaries have high security and good liquidity, the financial market is greatly affected by macroeconomic, fiscal and monetary policies, and it cannot be ruled out that this investment may be affected by market fluctuations.
(2) Risk prevention and control measures
The company and its subsidiaries will handle relevant cash management business in strict accordance with relevant regulations such as the "Regulatory Guidelines for Listed Companies No. 2 - Supervisory Requirements for the Management and Use of Raised Funds by Listed Companies", the "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations" and the company's "Measures for the Management of Raised Funds" and other relevant regulations. The Finance Department will pay attention to and analyze the investment direction and progress of cash management products in real time. Once it is discovered or judged that there are factors that affect the income of cash management products, it should promptly notify the company's operating management and take corresponding preservation measures to control investment risks to the maximum extent and ensure the safety of funds.
Complete and complete accounting accounts should be established for economic activities involving the use of funds, and financial accounting for the use of funds should be done; the finance department should check the account balance with the bank in a timely manner on the day of investment events to ensure the safety of funds.
The company’s independent directors and board of supervisors have the right to supervise and inspect the use of funds, and can hire professional institutions to conduct audits when necessary.
5. The impact of cash management on the company
The company uses part of the idle raised funds for cash management under the premise of ensuring the safety of the raised funds and not affecting the normal progress of the raised funds investment plan. It will not affect the company's daily operations and the normal implementation of the raised funds investment projects. There will be no harm to the interests of the company and shareholders, and there will be no disguised change in the use of raised funds. Through appropriate and timely cash management of some idle raised funds, the efficiency of use of raised funds can be improved, the company's cash asset income can be increased, and better investment returns can be obtained for the company's shareholders. The proceeds from the company and its subsidiaries using idle raised funds for cash management belong to the company and its subsidiaries, and the funds are managed and used in strict accordance with the requirements of the China Securities Regulatory Commission and the Shanghai Stock Exchange on regulatory measures for raised funds. The cash management products will be returned to the special account for raised funds after expiration.
6. As of the date of this announcement, the use of raised funds for cash management during the authorization period
Unit: RMB 10,000 serial number Cash management type Actual investment amount Actual principal recovered Actual income Amount of principal not yet recovered 1 Ordinary large-denomination certificate of deposit 10,000.00 10,000.00 67.51 0 2 Ordinary large-denomination certificate of deposit 20,000.00 20,000.00 135.00 0 3 Ordinary large-denomination certificate of deposit 8,000.00 8,000.00 54.01 0 4 Ordinary large-denomination certificate of deposit 1,000.00 1,000.00 6.75 0 5 Ordinary large-denomination certificate of deposit 1,000.00 1,000.00 6.75 0 6 Ordinary large-denomination certificate of deposit 5,000.00 5,000.00 11.25 0 7 Ordinary large-denomination certificate of deposit 49,500.00 49,500.00 334.19 0 8 Ordinary large-denomination certificate of deposit 4,000.00 4,000.00 27.01 0 9 Ordinary large-denomination certificate of deposit 2,000.00 2,000.00 4.50 0 10 Ordinary large-denomination certificate of deposit 4,000.00 4,000.00 9.00 0 11 Ordinary large-denomination certificate of deposit 2,100.00 2,100.00 14.18 0 12 Ordinary large-denomination certificate of deposit 10,000.00 - - 10,000.00 13 Time deposit 1,500.00 - - 1,500.00 14 Ordinary certificate of deposit 6,000.00 - - 6,000.00
15 Ordinary large-denomination certificate of deposit 5,000.00 - - 5,000.00 16 Ordinary large-denomination certificate of deposit 45,000.00 - - 45,000.00 17 Ordinary large-denomination certificate of deposit 4,000.00 - - 4,000.00
Total 670.15 71,500.00 Total cash management quota of raised funds (10,000 yuan) 120,000.00 Cash management quota currently used (10,000 yuan) 71,500.00 Unused cash management quota (10,000 yuan) 48,500.00
Announcement is hereby made.
Board of Directors of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
October 30, 2025